GlaxoSmithKline

GlaxoSmithKline is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. The company aims to bring differentiated, high-quality and needed healthcare products to as many people as possible, with its 3 global businesses, scientific and technical know-how, and talented people. GSK's Pharmaceuticals business has a broad portfolio of innovative and established medicines with commercial leadership in respiratory and HIV. Our R&D approach focuses on science related to the immune system, the use of genetics, and advanced technologies. The Vaccines business has a broad portfolio and innovative pipeline of vaccines to help protect people throughout life. It delivers over two million vaccine doses per day to people living in over 160 countries. The Consumer Healthcare business develops and markets an innovative portfolio of consumer preferred and expert-recommended brands in the Pain relief, Respiratory, Digestive health, Oral Health, Nutrition, and Skin health categories.

Michael Elmore

SVP and Chief Information Security Officer

Nick Tate

VP Digital Innovation

45 past transactions

LifeMine Therapeutics

Series C in 2022
LifeMine Therapeutics combines genomics with AI and synthetic biology to discover and develop a pipeline of novel medicines. LifeMine’s Avatar-Rx platform integrates high-throughput microbiology, data science and machine learning, genome engineering, and automation technologies to search the fungal biosphere for novel GEMs having a predetermined target and biological function. The platform integrates chemoinformatic-assisted drug optimization and state-of-the-art chemical synthesis with biotransformation to advance new product candidates into development. Founded by Gregory Verdine, PhD, Rick Klausner, MD, and WeiQing Zhou, MBA. LifeMine Therapeutics is headquartered in Cambridge, Massachusetts.

Adrestia Therapeutics

Series A in 2020
Adrestia Therapeutics are leaders in synthetic rescue, an approach that decodes the complexity of genetic networks to reveal new ways to treat diseases.

CureVac

Corporate Round in 2020
CureVac is a clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA. The company develops drugs that are based on Messenger RNA (mRNA) as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. mRNA programs include novel mRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases (RNActive), molecular therapies designed to trigger the body’s own production of therapeutic proteins (RNArt), and RNA encoded antibodies (RNAntibody). Its most advanced product candidate, CV9104, is being developed in Phase IIb for the treatment of prostate cancer.

Vir Biotechnology

Post in 2020
Vir Biotechnology is a commercial-stage immunology company developing therapeutic products to treat and prevent serious infectious diseases. The company brings together cutting-edge innovations with scientific expertise and management. It seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. Vir Biotechnology also focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company four current technology platforms are designed to, either individually or in combination, stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Their vision is that one day, diseases like hepatitis B, influenza A, HIV, and tuberculosis become a thing of the past.

SetPoint Medical

Venture Round in 2019
SetPoint Medical is a privately held clinical-stage healthcare company dedicated to treating patients with chronic autoimmune diseases. The company is developing a novel platform designed to stimulate the vagus nerve to activate the inflammatory reflex to produce a systemic immune-restorative effect. SetPoint Medical’s platform technology is designed to offer patients and providers a treatment alternative for rheumatoid arthritis, inflammatory bowel disease and other chronic autoimmune conditions with potentially less risk and cost than drug therapy.

Sitari Pharmaceuticals

Acquisition in 2019
Sitari Pharmaceuticals is a operator of a biotechnology company intended to develop treatments for multiple disease indications with an initial focus in celiac disease.

SpringWorks Therapeutics

Series B in 2019
SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for patients living with severe rare diseases and cancer. SpringWorks has a differentiated targeted oncology pipeline spanning solid tumors and hematological cancers, including two potentially registrational clinical trials in rare tumor types as well as several programs addressing highly prevalent, genetically defined cancers. SpringWorks’ strategic approach and operational excellence in clinical development have enabled it to rapidly advance its two lead product candidates into late-stage clinical trials while simultaneously entering into multiple shared-value partnerships with innovators in industry and academia to unlock the full potential for its portfolio and create more solutions for patients with cancer.

TESARO

Acquisition in 2018
Founded in 2010, TESARO is a privately held oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. The Company intends to leverage the experience and competencies of its management team to identify, acquire and develop promising drug candidates; and to commercialize safer and more effective products for the treatment and support of cancer patients. TESARO is developing rolapitant, a potent, selective neurokinin-1 receptor antagonist that has completed Phase 2 clinical testing for the prevention of chemotherapy induced nausea and vomiting, and is advancing its ALK inhibitor program for oncology indications. Phase 3 clinical testing of rolapitant is planned to commence during 2011 and the first ALK inhibitor clinical trial is targeted to begin in 2012. TESARO was co-founded by former executives of MGI PHARMA, an oncology and acute-care focused biopharmaceutical company that Eisai Co., Ltd. acquired in 2008 for $3.9 billion. TESARO is headquartered in Waltham, Massachusetts.

23andMe

Corporate Round in 2018
23andMe is a human genome research company enabling users to study their ancestry, genealogy, and inherited traits. A startup co-founded by Linda Avey and Anne Wojcicki, the wife of Google co-founder Sergey Brin, 23andMe has plans to make the human genome searchable. Brin, along with Google, gave 23andMe $3.9 million as part of a series A in May of 2007. The company was named after the number of chromosome pairs in humans. They aim to help people understand what their genes mean by indexing them and highlighting significant findings. 23andMe allows its clients/users to study their ancestry, genealogy and inherited traits. The company also markets to researchers and scientists, for whom they provide neatly categorized and easily searchable data. One reason the Google investment in 23andMe made sense was that this company could enable the search giant to index another facet of the world's information. With the Biotech and Health Care industries growing rapidly, 23andMe could help Google get and maintain a market hold in these already multi-billion dollar areas.

Spero Therapeutics

Series B in 2016
Spero Therapeutics is developing first in class therapeutics for treatment of gram-negative infections. The company leverages a top-tier chemistry and microbiology team, an efficient virtual approach to drug development, and a focus on high potential, novel mechanisms to fill the unmet need for early stage therapeutics targeting serious bacterial infections. Its lead program addresses a novel target driving virulence and persistence of pseudomonas aeruginosa infections and other gram-negative pathogens.

Atreca

Series A in 2015
Atreca is a biopharmaceutical that develops a technology to identify the set of antibodies produced during an immune response, without prior knowledge of an antigen. Its product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target-derived from an antibody identified using its discovery platform.

Gladius Pharmaceuticals

Series A in 2015
Gladius Pharmaceuticals Inc., a Montréal-based biotechnology firm developing novel drugs to treat life-threatening, multi-drug-resistant bacterial infections.Gladius is a disruptive platform technology play, capable of developing multiple novel drug candidates

Spero Therapeutics

Series A in 2015
Spero Therapeutics is developing first in class therapeutics for treatment of gram-negative infections. The company leverages a top-tier chemistry and microbiology team, an efficient virtual approach to drug development, and a focus on high potential, novel mechanisms to fill the unmet need for early stage therapeutics targeting serious bacterial infections. Its lead program addresses a novel target driving virulence and persistence of pseudomonas aeruginosa infections and other gram-negative pathogens.

GlycoVaxyn

Acquisition in 2015
GlycoVaxyn AG is a biopharmaceutical company based in Schlieren, Switzerland, specializing in the development and manufacture of biological conjugation vaccines aimed at preventing bacterial infections. Established in 2004, the company utilizes recombinant DNA technology to create immunogenic glycoprotein conjugate vaccines for various bacterial diseases, including pneumococcal and nosocomial infections. GlycoVaxyn's innovative approach allows for the conjugation of carbohydrates to proteins, resulting in well-characterized molecules with high consistency and reproducibility across batches. This technology supports the development of new prophylactic and therapeutic vaccines, contributing to advancements in the treatment and prevention of bacterial infections. As of early 2015, GlycoVaxyn operates as a subsidiary of GlaxoSmithKline plc.

Silarus Therapeutics

Series A in 2014
Silarus Therapeutics is developing therapeutics targeting erythroferrone for the treatment of iron deficiency and iron overload disorders. Erythroferrone is a recently-discovered hormone that regulates the iron supply for red blood cell production. Iron deficiency, also known as anemia, is a condition in which blood does not contain the normal amount of red blood cells or lacks the proper amount of hemoglobin. This, in turn, lowers the amount of oxygen-rich blood in circulation, causing shortness of breath, dizziness or headaches.

Thyritope Biosciences

Series A in 2014
Thyritope Biosciences is developing therapeutics that target thyroid stimulating auto-antibodies, which are the causative drivers of Graves' hyperthyroidism and Graves' orbitopathy. Graves' disease is an autoimmune disorder caused by antibodies that over-stimulate the thyroid, causing excessive thyroid hormone production. The same antibodies stimulate the tissue around the eyes, resulting in an increase of orbital fat and extra-ocular muscle volume which causes the bulging of the eyes characteristic of Graves' orbitopathy.

Sitari Pharmaceuticals

Series A in 2013
Sitari Pharmaceuticals is a operator of a biotechnology company intended to develop treatments for multiple disease indications with an initial focus in celiac disease.

SetPoint Medical

Series C in 2013
SetPoint Medical is a privately held clinical-stage healthcare company dedicated to treating patients with chronic autoimmune diseases. The company is developing a novel platform designed to stimulate the vagus nerve to activate the inflammatory reflex to produce a systemic immune-restorative effect. SetPoint Medical’s platform technology is designed to offer patients and providers a treatment alternative for rheumatoid arthritis, inflammatory bowel disease and other chronic autoimmune conditions with potentially less risk and cost than drug therapy.

Okairos

Acquisition in 2013
Okairos AG, a bio-pharmaceutical company, focuses on the discovery and development of genetic T-cell vaccines, including hepatitis C virus. The company also provides health and allied services. It has operations in Rome and Naples, Italy. The company is based in Basel, Switzerland. Okairos AG was former subsidiary of Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa.

NeRRe Therapeutics

Series A in 2012
NeRRe Therapeutics Ltd. operates as a biotechnology company that develops clinical and pre-clinical neurokinin receptor antagonists. The company was founded in 2012 and is based in Stevenage, United Kingdom.

Human Genome Sciences

Acquisition in 2012
GlaxoSmithKline (GSK) is a global healthcare company that is committed to helping people to do more, feel better, and live longer.

Amicus Therapeutics

Post in 2012
Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases. The Company has a robust pipeline of novel, first-in-class, small molecules called pharmacological chaperones for the treatment of lysosomal storage diseases (LSDs). These chaperones may offer a dual-treatment approach for Fabry, Pompe, Gaucher and other LSDs. As orally administered monotherapy agents, pharmacological chaperones are designed to bind to, stabilize and increase the activity of a patient’s own misfolded enzyme. In combination with enzyme replacement therapy (ERT), pharmacological chaperones may improve the uptake of the infused enzyme and potentially improve ERT outcomes.

CellZome

Acquisition in 2012
CellZome is a pharmaceutical company that discovers, develops, and commercializes kinase-targeted drugs for the treatment of inflammatory diseases. It develops a pipeline of kinase inhibitors targeting inflammatory mediators as oral therapeutics for rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, psoriasis, and asthma. CellZome was founded in 2000 and is based in Heidelberg, Baden-Wurttemberg.

Epizyme

Venture Round in 2011
Epizyme is a biopharmaceutical company located in Cambridge, MA, that is focused on researching treatments for blood cancer and tumors. Founded in late 2007, the company has brought together premier academic and industry leaders to rapidly translate the exciting discoveries emerging from epigenetic research into specific programs that will produce important, novel, molecularly targeted drugs of the future.

Concert Pharmaceuticals

Venture Round in 2011
Concert Pharmaceuticals is a clinical-stage biotechnology company dedicated to creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium. Concert applies its innovative precision deuterium chemistry platform to modify specific properties of validated drug molecules, yielding a rich pipeline of new chemical entities (NCEs). Concert leverages decades of pharmaceutical experience to create novel drug candidates with the potential for efficacy and safety, while greatly reducing R&D risk, time, and expense.

Semprus BioSciences

Series B in 2010
Semprus BioSciences is a venture-backed biomedical company headquartered in Cambridge, Massachusetts. Our innovative, multi-faceted Semprus technology signifies a breakthrough in medical device technology. Our current focus is to develop a vascular access catheter with the first single surface modification that is designed to simultaneously reduce microbial adherence and thrombus accumulation over the life of the device. In December 2010, the company completed an $18 million Series B financing co-led by SR One, the corporate venture capital arm of GlaxoSmithKline, and Foundation Medical Partners (FMP), a national healthcare venture capital investment firm with a strategic relationship with Cleveland Clinic. Combined with previous financing rounds, Semprus has raised a total of $28.5 million in equity.

MaxiNutrition

Acquisition in 2010
MaxiNutrition manufactures protein-enhanced functional nutrition products. Maxinutrition, the parent company of Maximuscle, Maxifuel and Maxitone, is Europe’s leading sports nutrition company. Maximuscle is targeted at consumers who are focused on gaining muscle and increasing strength and power. Maxifuel was launched in June 2010 with a new range of products designed for endurance, targeting sports men and women to whom performance is critical. Maxitone is a product range designed for healthy active women to aid toning and weight management.

Nanjing MeiRui Pharma Co., Ltd.

Acquisition in 2010
Nanjing MeiRui Pharma Co., Ltd. operates as a pharmaceutical business with a strong portfolio of urology and allergy products, including Prostat for benign prostatic hyperplasia and Sheniting for overactive bladder syndrome.

Laboratorios Phoenix

Acquisition in 2010
Laboratorios Phoenix is a global pharmaceutical company based in Argentina.

NovaMin Technology

Acquisition in 2010
NovaMin Technology provides a range of oral hygiene solutions. The company was founded by Randy Scott in 2004 and is based in Alachua, Florida.

NeuroTherapeutics Pharma

Series B in 2010
NeuroTherapeutics Pharma, Inc., a biopharmaceutical company, develops therapeutics for patients suffering from central nervous system disorders. It focuses on epilepsy, neuropathic, and acute pain disorders of the nervous system. The company was incorporated in 2006 and is based in Chicago, Illinois.

Genmab

Post in 2009
Genmab is a biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer. Its discovery, development, and manufacturing teams are using cutting-edge technology to create and develop products to address unmet medical needs.

Chroma Therapeutics

Series D in 2009
Chroma Therapeutics is a privately-held biotechnology company focused on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. Chroma is the first company to systematically assemble intellectual property in chromatin biology and has established a strong network of academic collaborators. Chroma aims to build substantial shareholder value through the creation of a broad and innovative product pipeline aimed at the treatment of high-prevalence cancers and inflammatory disorders.

Stiefel

Acquisition in 2009
Stiefel, a [GSK](/organization/glaxosmithkline) company, works to advance dermatology and skin science around the world. The company’s deeply-rooted dedication and drive for innovation along with its sole focus on dermatology has led Stiefel to become the largest independent dermatology company in the world. In addition to more than 30 wholly-owned subsidiaries, six manufacturing plants and a global research and development network, Stiefel’s most valuable asset is its global network of nearly 3,500 driven associates. By combining expertise, knowledge and imagination, Stiefel delivers exceptional ethical, over-the-counter and aesthetic products to its customers in more than 100 countries around the world, ultimately providing a unique Stiefel skin health experience. Stiefel is also committed to improving today’s treatments and exploring tomorrow’s innovations. Each year, the company invests more than $100 million in developing the most advanced skin health solutions.

Genelabs Technologies

Acquisition in 2008
As of January 6, 2009, Genelabs Technologies Inc. was acquired by SmithKline Beecham Corporation. Genelabs Technologies, Inc., a biopharmaceutical company, engages in the discovery and development of infectious disease therapies to improve human health. The company's product pipeline consists of infectious disease projects focusing on Hepatitis C virus infection; and late-stage clinical assets, including an investigational vaccine for hepatitis E virus that is being developed by GlaxoSmithKline; and Prestara, an investigational drug for systemic lupus erythematosus. It has license and collaboration agreement with the Novartis Institutes for BioMedical Research for HCV polymerase non-nucleoside discovery research. Genelabs Technologies also has a collaborative research agreement with the National Health Research Institutes and Genovate Biotechnology Co., Ltd. to discover and develop compounds that target the hepatitis C virus. The company was founded in 1983 and is headquartered in Redwood City, California.

BMS - Egyptian Mature Products Business

Acquisition in 2008
BMS - Egyptian Mature Products Business provides pharmaceutical products.

Sirtris Pharmaceuticals

Acquisition in 2008
[Sirtris Pharmaceuticals](http://www.sirtrispharma.com) (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. via: [Sirtris](http://www.sirtrispharma.com)

Reliant Pharmaceuticals

Acquisition in 2007
Reliant Pharmaceuticals provides cardiovascular pharmaceutical products. It is engaged in the sale and marketing of these products. Its product portfolio includes Axid, a nizatidin; InnoPran XL and DynaCirc CR for the treatment of hypertension; Omacor to reduce high triglycerides; and Rythmol SR. It provides products for the treatment of elevated cholesterol and triglycerides, acid reflux disease, and prevention of coronary complications in patients with coronary heart disease. It distributes its products to physicians engaged in primary care, cardiovascular, and specialized medical areas. Reliant Pharmaceuticals was established in 1999, headquartered in Liberty Corner, New Jersey.

Praecis Pharmaceuticals, Inc.

Acquisition in 2006
Praecis Pharmaceuticals, Inc. operates as a biopharmaceutical company, engages in the discovery and development of novel compounds to address unmet medical needs or improve existing therapies.

Domantis Ltd.

Acquisition in 2006
Domantis Ltd. develops antibody molecules. Domantis Ltd. offers dual targeting human domain antibodies, which are used against cytokine targets for inflammatory diseases, tumour antigens present on the same tumour cells, and tumour growth/angiogenic factors for solid tumours; human domain antibodies with tailored serum half-life that are customized to achieve the desired therapeutic effect; human domain antibodies for diverse therapeutic targets, which are suited to inhibit receptor targets; and injectable and non-injectable human domain antibodies that treat diseases of the lung, as well as disorders of the gastro-intestinal tract.

CNS

Acquisition in 2006
CNS, Inc. was acquired by GlaxoSmithKline Consumer Healthcare, L.P. CNS, Inc. engages in the development and marketing of consumer health care products for better breathing and digestive health markets. The company’s primary products include Breathe Right nasal strips, a nonprescription single-use disposable device that improves breathing by opening the nasal passages; Breathe Right Snore Relief throat spray, a drug-free product that addresses the snoring condition; Breathe Right Vapor Shot! personal vaporizer; Breathe Right saline nasal spray; and FiberChoice, an orange-flavored chewable fiber tablet that supplements the consumer’s daily intake of dietary fiber. CNS markets its products through direct sales force and national brokerage organizations to mass merchandise stores, drug stores, grocery stores, warehouse clubs, military base stores, and online retailers in the United States, as well as through distributors, sales representatives, and suppliers internationally. The company was founded in 1982 and is headquartered in Minneapolis, Minnesota. Source : (Businessweek) {http://investing.businessweek.com/research/stocks/private/snapshot.asp?privcapId=171706}

ID Biomedical

Acquisition in 2005
ID Biomedical Corporation develops and markets vaccine products. The company markets Fluviral, an injectable vaccine for influenza, as well as NeisVac-C for Meningococcal Group C disease in Canada. It also distributes NeisVac-C under license from Baxter Corporation.

Corixa

Acquisition in 2005
Corixa is a developer of immunotherapeutics with a commitment to treating and preventing autoimmune diseases, cancer and infectious diseases by understanding and directing the immune system. Having founded in 1994, the company conducted various preclinical development programs, including the BEXXAR® therapy and the MELACINE® vaccine. Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary product components on a standalone basis. The company partners with numerous developers and marketers of pharmaceuticals, targeting products that are powered by Corixa™ technology with the goal of making its potential products available to patients around the world. Corixa was acquired by GlaxoSmithKline on 12 July 2005, and GSK had formerly made use of the Corixa's MPL adjuvant in some of their vaccines. The company ceased operations in March 2006.

Europharm Holding SA

Acquisition in 2003
Europharm Holding SA distributes pharmaceutical products. Europharm Holding operates as a subsidiary of GlaxoSmithKline.

Block Drug Co., Inc.

Acquisition in 2001
Block Drug Co., Inc. manufactures denture care products, oral health care products, consumer over-the-counter medications, and professional dental products.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.